KULR · KULR Technology Group, Inc.

Represents the number of shares of Common Stock that were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units ("RSUs") previously granted under the Issuer's equity incentive plan and does not represent a sale.

Represents the previous closing price of the Issuer's Common Stock on the vesting date and does not represent a sale.

Represents the number of shares of Common Stock that were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units ("RSUs") previously granted under the Issuer's equity incentive plan and does not represent a sale.

Represents the previous closing price of the Issuer's Common Stock on the vesting date and does not represent a sale.

Represents the number of shares of Common Stock that were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units ("RSUs") previously granted under the Issuer's equity incentive plan and does not represent a sale.

Represents the previous closing price of the Issuer's Common Stock on the vesting date and does not represent a sale.

Amount has been adjusted pursuant to a one-for-eight reverse stock split effected on June 23, 2025 and to include shares underlying previously granted restricted stock units that were previously omitted from this amount.

Represents the number of shares of Common Stock that were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units ("RSUs") previously granted under the Issuer's equity incentive plan and does not represent a sale.

Represents the previous closing price of the Issuer's Common Stock on the vesting date and does not represent a sale.

Amount has been adjusted pursuant to a one-for-eight reverse stock split effected on June 23, 2025 and to include shares underlying previously granted restricted stock units that were previously omitted from this amount.

Represents the number of shares of Common Stock that were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units ("RSUs") previously granted under the Issuer's equity incentive plan and does not represent a sale.

Represents the previous closing price of the Issuer's Common Stock on the date the RSU first became eligible for settlement and does not represent a sale.

Amount has been adjusted pursuant to a one-for-eight reverse stock split effected on June 23, 2025 and to include shares underlying previously granted restricted stock units that were previously omitted from this amount.

Represents the number of shares of Common Stock that were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units ("RSUs") previously granted under the Issuer's equity incentive plan and does not represent a sale.

Represents the previous closing price of the Issuer's Common Stock on the vesting date and does not represent a sale.

Amount has been adjusted pursuant to a one-for-eight reverse stock split effected on June 23, 2025 and to include shares underlying previously granted restricted stock units that were previously omitted from this amount.

All share and share related information gives retrospective effect to the 8-to-1 reverse stock split effective on June 23, 2025.

Represents the number of shares of Common Stock that were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units ("RSUs") previously granted under the Issuer's equity incentive plan and does not represent a sale.

Represents the previous closing price of the Company's Common Stock on the vesting date and does not represent a sale.

Beneficial ownership set forth in Column 5 consists of the 13,945 shares net settled on December 6, 2025 after satisfying tax withholding and remittance obligations, and does not include the 164,062 shares underlying all remaining RSUs held by Mr. Yamamoto, not expected to settle or vest within 60 days of this Form 4.

The beneficial ownership set forth in Column 5 does not include Mr. Yamamoto's indirect ownership of 6,582 shares owned by his spouse and through his spouse's IRA. Mr. Yamamoto does not have direct voting or dispositive control over the shares owned by his spouse.

On November 24, 2025 on recommendation of the Compensation Committee of the Board of Directors ("Board") of the Company, the Board approved the issuance of 187,500 restricted stock units of common stock of the Company.

On November 26, 2025, the Company issued Mr. Yamamoto, 187,500 restricted stock units of common stock of the Company, under its 2025 Equity Incentive Plan. The shares will vest in eight equal semi-annual installments, with 23,438 RSUs vesting on December 6, 2025, followed by alternating installments of 23,437 RSUs and 23,438 RSUs every six months thereafter. The vesting of shares is subject to Mr. Yamamoto's continued service with the Company.

All share and share related information gives retrospective effect to the 8-to-1 reverse stock split effective on June 23, 2025.

The number of shares of common stock beneficially owned following the reported transactions does not include Mr. Yamamoto's indirect ownership of 6,581 shares owned by his spouse and through his spouse's IRA. Mr. Yamamoto does not have direct voting or dispositive control over the shares owned by his spouse.

On November 24, on recommendation of the Compensation Committee of the Board of Directors ("Board") of the Company, the Board approved the issuance of 13,130 restricted stock units of common stock of the Company.

On November 26, 2025, the Company issued Mr. Schwartz, as board compensation, 13,130 restricted stock units of common stock of the Company, under its 2025 Equity Incentive Plan. The shares will vest in two equal installments, with 6,565 RSU shares vesting on December 6, 2025, and 6,565 RSU shares will vest six months thereafter. The vesting of shares is subject to Mr. Schwartz's continued services with the Company.

All share and share related information gives retrospective effect to the 8-to-1 reverse stock split effective on June 23, 2025.

On November 24, 2025 on recommendation of the Compensation Committee of the Board of Directors ("Board") of the Company, the Board approved the issuance of 13,130 restricted stock units of common stock of the Company.

On November 26, 2025, the Company issued Ms. Grier, as board compensation, 13,130 restricted stock units of common stock of the Company, under its 2025 Equity Incentive Plan. The shares will vest in two equal installments, with 6,565 RSU shares vesting on December 6, 2025, and 6,565 RSU shares will vest six months thereafter. The vesting of shares is subject to Ms. Grier's continued services with the Company.

All share and share related information gives retrospective effect to the 8-to-1 reverse stock split effective on June 23, 2025.

Reflects (i) 17,500 shares underlying the equity incentive grant of restricted stock units to the Reporting Person as board compensation, effective April 15, 2024, with all shares of such grant fully vested; and (ii) 13,130 restricted stock units of common stock of the Company, being reported on this Form 4.

On November 24, 2025 on recommendation of the Compensation Committee of the Board of Directors ("Board") of the Company, the Board approved the issuance of 13,130 restricted stock units of common stock of the Company.

On November 26, 2025, the Company issued Dr. Massey, as board compensation, 13,130 restricted stock units of common stock of the Company, under its 2025 Equity Incentive Plan. The shares will vest in two equal installments, with 6,565 RSU shares vesting on December 6, 2025, and 6,565 RSU shares will vest six months thereafter. The vesting of shares is subject to Dr. Massey's continued services with the Company.

All share and share related information gives retrospective effect to the an 8-to-1 reverse stock split effective on June 23, 2025.

Reflects (i) 17,813 shares underlying various equity incentive grants of restricted stock units to the Reporting Person as board compensation, with all shares of such grants fully vested; and (ii) 13,130 restricted stock units of common stock of the Company, being reported on this Form 4.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on July 1, 2025.

Represents the number of shares automatically sold pursuant to the Rule 10b5-1 trading plan to satisfy the Reporting Person's income tax remittance obligations in connection with previously vested restricted stock units.

Represents the number of shares of Common Stock that were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units ("RSUs") previously granted under the Issuer's equity incentive plan and does not represent a sale.

Represents the previous closing price of the Company's Common Stock on the vesting date and does not represent a sale.

Beneficial ownership set forth in Column 5 consists of the 8,020 shares settled net on August 22, 2025 to satisfy tax withholding and remittance obligations, the 21,875 shares previously vested to Mr. Walker and does not include the 154,687 shares underlying all remaining RSUs held by Dr. Walker, not expected to settle or vest within 60 days of this Form 4.

Represents the number of shares of Common Stock that were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units ("RSUs") previously granted under the Issuer's equity incentive plan and does not represent a sale.

Represents the previous closing price of the Company's Common Stock on the vesting date and does not represent a sale.

Beneficial ownership set forth in Column 5 consists of the 16,498 shares settled on August 22, 2025 net of tax withholding and remittance obligations for RSUs that vested on June 30, 2025, and the 62,500 shares of Common Stock held directly by Mr. Carpenter.

Represents the number of shares of Common Stock that were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units ("RSUs") previously granted under the Issuer's equity incentive plan and does not represent a sale.

Represents the previous closing price of the Company's Common Stock on the vesting date and does not represent a sale.

Beneficial ownership set forth in Column 5 consists of the 193,782 shares settled net of tax withholding and remittance obligations and: (i) 19,755,110 shares held directly by Mr. Mo; and (ii) 1,400,000 shares held jointly by Mr. Mo and his spouse. Does not include restricted stock awards of 3,500,000 shares of the Issuer's common stock that does not vest or settle within 60 days and does not include 1,000,000 shares of Non-Convertible Series A Voting Preferred, which entitles Mr. Mo to votes equal to one hundred votes per share.

Represents the number of shares of Common Stock that were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units ("RSUs") previously granted under the Issuer's equity incentive plan and does not represent a sale.

Represents the previous closing price of the Company's Common Stock on the vesting date.

Excludes the unvested portion of (i) 1,500,000 RSUs originally granted on March 31, 2023, that vests in five (5) equal annual installments through March 31, 2028, and (ii) 1,500,000 RSUs originally granted on January 16, 2025 that vest in four (4) equal annual installments through January 16, 2029. Each RSU represents the right to receive one share of Common Stock upon settlement.

The Company issued 270,000 shares of Non-Convertible Series A Voting Preferred Stock to the Chairman and Chief Executive Officer, Michael Mo, in accordance with a resolution passed by the Company's Board of Directors and the prior approval of the majority stockholders of the Company. This issuance is part of a strategic initiative to reinforce and enhance the Company's flexibility to optimize its negotiating position in any potential current and/or future engagements with commercial, financial, and/or strategic parties, and to provide defenses against potential hostile third-party actions.

Effective January 16, 2025, the Board of Directors ("Board") of KULR Technology Group, Inc. (the "Company"), at the recommendation of the Compensation Committee of the Board, approved a restrict stock unit grant ("RSU") to Mr. Canter in the amount of 1,500,000 shares of the Company's common stock. The 1,500,000 shares are subject to vesting in four (4) equal annual installments with the first installment vesting on January 17, 2026. The beneficial ownership set forth in Column 5 includes the 1,500,000 shares underlying the grant described above and includes 1,500,000 shares of common stock underlying the RSU grants previously issued to Mr. Canter, even though they are not all expected to settle or vest within 60 days of this Form 4.

The beneficial ownership set forth in Column 5 includes the shares underlying all RSUs held by Mr. Canter, even though they are not all expected to settle or vest within 60 days of this Form 4.

Effective January 16, 2025, the Board of Directors ("Board") of KULR Technology Group, Inc. (the "Company"), at the recommendation of the Compensation Committee, approved a restrict stock unit grant ("RSU") to Mr. Carpenter in the amount of 200,000 shares of the Company's common stock. The 200,000 shares underlying the aforementioned RSU grant will vest on June 30, 2025, subject to Mr. Carpenter's continued services to the Company. The beneficial ownership set forth in Column 5 includes the 200,000 shares underlying the grant described above and includes 500,000 shares of common stock held directly by Mr. Carpenter.

The beneficial ownership set forth in Column 5 the shares underlying the RSUs held by Mr. Carpenter, even though it is not expected to settle or vest within 60 days of this Form 4.

Effective January 16, 2025, the Board of Directors ("Board") of KULR Technology Group, Inc. (the "Company"), at the recommendation of the Compensation Committee of the Board approved a restrict stock unit grant ("RSU") to Mr. Mo in the amount of 2,000,000 shares of the Company's common stock. The 2,000,000 shares are subject to vesting in four (4) equal annual installments with the first installment vesting on January 17, 2026. The beneficial ownership set forth in Column 5 includes the 2,000,000 shares underlying the grant described above and includes 22,941,340 shares of common stock, which consists of: (i) 19,755,110 shares held directly by Mr. Mo; (ii) 1,400,000 shares held jointly by Mr. Mo and his spouse; and (iii) RSU awards for an aggregate of 1,786,230 shares of the Company's common stock even though such RSUs are not all expected to settle within 60 days of this Form 4.

The beneficial ownership set forth in Column 5 includes the shares underlying all RSUs held by Mr. Mo, even though they are not all expected to settle or vest within 60 days of this Form 4.

Effective January 16, 2025, the Board of Directors ("Board") of KULR Technology Group, Inc. (the "Company"), at the recommendation of the Compensation Committee of the Board, approved a restrict stock unit grant ("RSU") to Dr. Walker in the amount of 1,000,000 shares of the Company's common stock. These shares vest in four equal annual installments, with the first annual vest to occur on January 17, 2026, subject to Dr. Walker's continued services to the Company. The beneficial ownership set forth in Column 5 includes the 1,000,000 shares underlying the grant described above and includes the 500,000 shares underlying the RSU grants previously issued to Dr. Walker, even though they are not all expected to settle or vest within 60 days of this Form 4.

The beneficial ownership set forth in Column 5 includes the shares underlying all RSUs held by Dr. Walker, even though they are not all expected to settle or vest within 60 days of this Form 4.

On June 6, 2024, Mr. Cochran sold 108,079 shares of Issuer's common stock at an average price of $0.2909 per share. The sale price represents the weighted average sale price for multiple transactions reported. Upon request by the Commission, the Issuer or the Reporting Person shall provide full information regarding the number of shares purchased at each separate price.

Represents beneficial ownership after giving effect to an additional decrease of 122,000 shares reflecting a division of the Vested Shares with the Reporting Person's former spouse pursuant to a divorce settlement agreement.

On June 5, 2024, Mr. Cochran sold 119,754 shares of Issuer's common stock at an average price of $0.31 per share. The sale of shares was partly to satisfy the remainder of the tax withholding and remittance obligations. The sale price represents the weighted average sale price for multiple transactions reported. Upon request by the Commission, the Issuer or the Reporting Person shall provide full information regarding the number of shares purchased at each separate price.

As previously reported, as compensation for his services as President and Chief Operating Officer of the Issuer, the Reporting Person was granted 2,000,000 Restricted Shares of the Issuer's Common Stock subject to four (4) equal yearly installments, with the first installment amount vesting on March 1, 2022, and annually thereafter. The third 500,000 share installment vested on March 1, 2024 ("Vested Shares"), which Vested Shares were delivered to the Reporting Person on June 3, 2024.

On June 4, 2024, Mr. Cochran sold 150,167 shares of Issuer's common stock at an average price of $0.3143 per share. The sale of shares was to satisfy income tax withholding and remittance obligations in connection with the net settlement of 500,000 Vested Shares. The sale price represents the weighted average sale price for multiple transactions reported. Upon request by the Commission, the Issuer or the Reporting Person shall provide full information regarding the number of shares purchased at each separate price.

Effective May 23, 2024, the Compensation Committee of the Board of Directors of KULR Technology Group, Inc. (the "Company") approved a modification to the compensation arrangement for the reporting person, Michael Mo, the Chief Executive Officer ("CEO") of the Company. Pursuant to the modification, the CEO voluntarily agreed to a reduction in the cash component of his compensation by $112,344. In lieu of the reduced cash compensation, the CEO was issued restricted stock units of the Company for 286,230 shares of common stock. The shares will only vest after one year. The number of such restricted stock units was determined by dividing $112,344 by the closing price of the Company's common stock on May 22, 2024.

The beneficial ownership set forth in Column 5 includes the shares underlying the restricted stock units, even though they are not expected to vest within 60 days of this Form 4.

On April 12, 2024, KULR Technology Group, Inc. (the "Company") approved the issuance, effective April 15, 2024, to Dr. Joanna Massey, as board compensation, 15,000 shares of the Company's common stock, being shares of common stock awarded as equity incentive compensation for her year to date services, through March 31, 2024, as the Company's non-executive director.

Reflects restricted stock units of common stock of KULR Technology Group, Inc. (the "Company"), granted by the Company to the reporting person effective April 15, 2024, which is also the effective date of the reporting person's appointment as a director of the Company. These shares vest in four equal quarterly installments, of which 35,000 shares will vest on June 30, 2024, and 35,000 shares will vest quarterly thereafter. The vesting of shares is subject to Ms. Grier's continued services with the Company.

The beneficial ownership set forth in Column 5 includes the shares underlying the restricted stock units, even though they are not expected to vest within 60 days of this Form 4.

On April 12, 2024, the Company issued Dr. Massey, as board compensation, restricted stock units of common stock of the Company, effective April 15, 2024. These shares vest in four equal quarterly installments, of which 35,000 shares will vest on June 30, 2024, and 35,000 shares will vest quarterly thereafter. The vesting of shares is subject to Dr. Massey's continued services with the Company.

Reflects (i) 20,000 restricted shares of the Company's common stock granted to the reporting person, on June 7, 2021, the effective date of the reporting person's appointment as a director of the Company, which shares previously vested; (ii) 10,000 shares of common stock previously acquired, (iii) 37,500 shares underlying an equity incentive grant issued, on November 1, 2022, as Board compensation, which shares previously vested; (iv) 15,000 shares of the Company's common stock, being reported on this Form 4; and (v) 140,000 shares underlying an equity incentive grant issued, effective April 15, 2024, as Board compensation, of which 35,000 shares will vest on June 30, 2024, and the remainder of the shares will vest quarterly thereafter.

On April 12, 2024, KULR Technology Group, Inc. (the "Company") approved the issuance, effective April 15, 2024, to Morio Kurosaki, as board compensation, 15,000 shares of the Company's common stock, being shares of common stock awarded as equity incentive compensation for his year to date services as the Company's non-executive director.

Reflects (i) restricted shares of the Company's common stock granted to the reporting person, on June 7, 2021, the effective date of the reporting person's appointment as a director of the Company, which shares previously vested; (ii) 400,000 shares of common stock previously acquired, (iii) 37,500 shares underlying an equity incentive grant issued, on November 1, 2022, as Board compensation, which shares previously vested; and (iv) 15,000 shares of the Company's common stock, being reported on this Form 4.

Dr. Knowles, in order to make proceeds available for extraordinary medical expense obligations, sold shares pursuant to the limitations set forth in Rule 144(e) with respect to the amount of securities eligible for sale during any three month period.

On March 25, 2024, Dr. Knowles sold 361,338 shares of Issuer's common stock (the maximum number of shares remaining under the Rule 144(e) limitation) at an average price of $0.294427 per share. Upon request by the Commission, the Reporting Person shall provide full information regarding the number of shares sold at each separate price.

The number of shares of common stock beneficially owned following the reported transactions does not include Dr. Knowles' indirect ownership of over 670,360 shares owned by his spouse, Marianne Knight. Dr. Knowles does not have direct voting or dispositive control over the shares owned by Ms. Knight.

Dr. Knowles, in order to make proceeds available for extraordinary medical expense obligations, sold shares pursuant to the limitations set forth in Rule 144(e) with respect to the amount of securities eligible for sale during any three month period.

On March 22, 2024, Dr. Knowles, sold 460,037 shares of common stock of the Company at an average price of $0.222419 per share. Upon request by the Commission, the Reporting Person shall provide full information regarding the number of shares sold at each separate price.

The number of shares of common stock beneficially owned following the reported transactions does not include Dr. Knowles' indirect ownership of over 670,360 shares owned by his spouse, Marianne Knight. Dr. Knowles does not have direct voting or dispositive control over the shares owned by Ms. Knight.

Dr. Knowles, in order to make proceeds available for extraordinary medical expense obligations, sold shares pursuant to the limitations set forth in Rule 144(e) with respect to the amount of securities eligible for sale during any three month period.

On March 21, 2024, Dr. Knowles, sold 510,598 shares of common stock of the Company at an average price of $0.228863 per share. Upon request by the Commission, the Reporting Person shall provide full information regarding the number of shares sold at each separate price.

The Company issued 730,000 shares of Non-Convertible Series A Voting Preferred Stock to the Chairman and Chief Executive Officer, Michael Mo, in accordance with a resolution passed by the Company's Board of Directors (the "Board") and the prior approval of the majority stockholders of the Company. This issuance is part of a strategic initiative to reinforce and enhance the Company's flexibility to optimize its negotiating position in any potential current and/or future engagements with commercial, financial, and/or strategic parties, and to provide defenses against potential hostile third-party actions.

The Reporting Person pledged the common stock to secure the Reporting Person's promissory note with a private lender. Pursuant to the loan agreements the lender foreclosed on the collateral because the aggregate value of the collateral decreased below a designated threshold. This transaction was initiated by the lender and not by the Reporting Person and does not represent open market sales by the Reporting Person. For purposes of this report the transfer price of the common stock was deemed equal to $0.20, which was the closing market price on January 8, 2024, the date of the foreclosure.

These shares were purchased by Mr. Mo in an underwritten public offering pursuant to the Company's "shelf" registration statement on Form S-3 (No. 333-257697) declared effective by the U.S. Securities and Exchange Commission on July 13, 2021.

Reflects restricted shares of common stock granted by KULR Technology Group, Inc. (the "Company) to the reporting person, on July 12, 2023. These shares vest in four equal quarterly installments, with the first annual vest to occur on July 12, 2024, subject to Dr. Walker's continued services to the Company. The beneficial ownership set forth in Column 5 includes the 350,000 shares underlying the grant described above and includes 150,000 shares underlying the RSA grants previously issued to Dr. Walker.

On June 29, 2023, Marianne Knight, Mr. Knowles' spouse, sold 61,756 shares of common stock of the Company at a price of $0.622223 per share.

The shares of common stock are held by the Reporting Person's spouse, Marianne Knight. Mr. Knowles does not have direct voting or dispositive control over the shares owned by Ms. Knight. The Amount of securities beneficially owned following the reported transactions do not include Mr. Knowles' direct ownership over 15,600,000 shares, which amount remains unchanged since Mr. Knowles' initial acquisition of the Company's common stock.

On June 28, 2023, Marianne Knight, Mr. Knowles' spouse, sold 38,244 shares of common stock of the Company at a price of $0.643546 per share.

The shares of common stock are held by the Reporting Person's spouse, Marianne Knight. Mr. Knowles does not have direct voting or dispositive control over the shares owned by Ms. Knight. The Amount of securities beneficially owned following the reported transactions do not include Mr. Knowles' direct ownership over 15,600,000 shares, which amount remains unchanged since Mr. Knowles' initial acquisition of the Company's common stock.

Represents the weighted average purchase price of $0.8673 per share. Upon request by the Commission, the Issuer or the Reporting Person shall provide full information regarding the number of shares purchased at each separate price.

Mr. Canter was granted a restrict stock award ("RSA") of 1,500,000 shares of the Issuer's common stock in connection with his appointment as the Issuer's Chief Financial Officer. The 1,500,000 shares are subject to vesting in five (5) equal annual installments with the first installment vesting on March 31, 2024. The beneficial ownership set forth in Column 5 does not include the shares underlying the RSA because they are not expected to vest within 60 days of this Form 4.

As previously reported, as compensation for his services as President and Chief Operating Officer of the Issuer, the Reporting Person was granted 2,000,000 Restricted Shares of the Issuer's Common Stock subject to four (4) equal yearly installments, with the first installment amount vesting on March 1, 2022 and annually thereafter. The second 500,000 share installment vested on March 1, 2023 ("Vested Shares"). On March 31, 2023, and effective as of March 1, 2023, the Issuer withheld and cancelled 175,000 shares of Common Stock to satisfy income tax withholding and remittance obligations in connection with the net settlement of 325,000 Restricted Shares. The withholding and cancellation of the 175,000 shares does not represent a sale.

Does not represent a sale. Represents the closing price per share of the Issuer's Common Stock on the trading day prior to the March 1, 2023 effective date of the share cancellation to satisfy income tax withholding and remittance obligations.

Represents (i) 155,947 shares after giving effect to a decrease of 117,548 shares from the total 273,495 shares previously reported on the Reporting Person's prior Form 4 following a division of property with the Reporting Person's former spouse pursuant to a pre-divorce agreement; (ii) a decrease of 1,840 shares from the total 273,495 shares previously reported on the Reporting Person's prior Form 4 following a sale that was triggered by a good til cancel order placed on shares the Reporting Person purchased prior to becoming employed by the Issuer; and (iii) an increase of 162,500 shares after giving effect to (x) the withholding of 175,000 shares from the Vested Shares to satisfy income tax withholding and remittance obligations; and (y) a decrease of 162,500 shares after giving effect to a division of the Vested Shares with the Reporting Person's former spouse pursuant to a pre-divorce agreement.

On November 1, 2022, the Issuer issued to Morio Kurosaki, as board compensation, an equity incentive grant for 37,500 shares of the Issuer's common stock, of which 7,500 shares vested immediately, 7,500 shares will vest on December 31, 2022 and 7,500 shares will vest quarterly thereafter.

Reflects (i) restricted shares of the Issuer's common stock granted to the reporting person, on June 7, 2021, the effective date of the reporting person's appointment as a director of the Company, which shares previously vested; (ii) 400,000 shares of common stock previously acquired, and (iii) 37,500 shares underlying an equity incentive grant issued, on November 1, 2022,as Board compensation, of which 7,500 have already vested, 7,500 will vest on December 31, 2022 and 7,500 will vest quarterly thereafter.

On November 1, 2022, pursuant to a Restricted Stock Unit Agreement by and between the Issuer and Mr. Mo, the Issuer granted to Mr. Mo 1,500,000 restricted stock units of the Issuer's shares of common stock to vest in four equal annual installments and which restricted stock units are subject to delayed settlement provisions.

On November 1, 2022, pursuant to a Restricted Stock Unit Agreement by and between the Issuer and Mr. Cochran, the Issuer granted to Mr. Cochran 1,500,000 restricted stock units of the Issuer's shares of common stock to vest in four equal annual installments and which restricted stock units are subject to delayed settlement provisions.

Reflects restricted shares of common stock granted by KULR Technology Group, Inc. (the "Company) to the reporting person, on November 1, 2022, the effective date of the reporting person's appointment as an officer of the Company. These shares vest in four equal quarterly installments, with the first annual vest to occur on November 1, 2023, subject to Dr. Walker's continued services to the Company. The beneficial ownership set forth in Column 5 includes the 100,000 shares underlying the grant described above and includes the 50,000 shares underlying the RSA grant previously issued to Dr. Walker. However, none of the shares thereunder are expected to vest within 60 days of this Form 4.

On June 10, 2021, the Issuer granted to Mr. Cochran a restricted stock grant of 1,500,000 shares of the Issuer's common stock, which shares were scheduled to vest in increments upon the Issuer's achievement of various market capitalization milestones. On November 1, 2022 the Board of Directors of the Issuer approved the termination of this grant. Since its issuance, none of the shares subject to this terminated grant vested.

On June 10, 2021, pursuant to a Non-Qualified Stock Option Agreement by and between the Issuer and Mr. Mo, the Issuer granted Mr. Mo a five year, non-qualified stock option grant to purchase up to 1,500,000 shares of the Company's common stock at a purchase price equal to $2.60 per share, which were scheduled to vest in increments upon the Issuer's achievement of various market capitalization milestones. On November 1, 2022 the Board of Directors of the Issuer approved the termination of the non-qualified stock option. Since its issuance, none of the shares subject to this terminated option vested.